GLAUKOS Corp
StreetZero Signal 57
About GLAUKOS Corp
Glaukos Corporation is a public ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Founded in 1998 and headquartered in Aliso Viejo, CA, it operates a B2B business model in the Medical Equipment Manufacturing industry. The company completed its IPO on the NYSE in June 2015 under ticker GKOS and continues to develop and commercialize products such as intracameral procedural pharmaceuticals and corneal cross-linking therapies.
LATEST FUNDINGRule 144
$215K
Announced 2026-11-16
TOTAL RAISED$182.20M
IN THE NEWS
- ๐ Glaukos Corporation
- ๐ Glaukos Corp Completed Its IPO This Week; Now Trades Near $28 Mark
- ๐ Glaukos - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- ๐ glaukos corporation
- ๐ Glaukos Corporation - Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
EMPLOYEESโ
FOUNDED1998
HQAliso Viejo, CA, United States
Industry
Public Equity (NYSE)
Tags
Medical DevicesOphthalmologyPublic CompanyGlaucoma
Investors
Key highlights
- Completed IPO in June 2015 on NYSE at $18 per share with full exercise of underwriter option.
- Raised total of $118M-$182M over 10 rounds prior to going public.
- Develops long-duration intracameral pharmaceuticals and FDA-approved corneal cross-linking therapies.
- Celebrated 10th anniversary of NYSE listing in June 2025.
- Q3 revenue reached $211M with strong growth in glaucoma and corneal franchises.
Ask StreetZero about GLAUKOS Corp
Put our AI to work on this deal.
Similar companies
Other Public Equity (NYSE) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account